Dr Kate Lynette Mahon

Boyer M; Mahon K, 2013, 'Testicle carcinoma surveillance counterpoint: Australia', in Patient Surveillance After Cancer Treatment, pp. 449 - 452, http://dx.doi.org/10.1007/978-1-60327-969-7_88

Boyer M; Mahon K, 2013, 'Lung carcinoma surveillance counterpoint: Australia', in Patient Surveillance After Cancer Treatment, pp. 75 - 78, http://dx.doi.org/10.1007/978-1-60327-969-7_13

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, vol. 10, pp. 1688 - 1699, http://dx.doi.org/10.21037/tau-20-1444

Scheinberg T; Young A; Woo H; Goodwin A; Mahon KL; Horvath LG, 2021, 'Mainstream consent programs for genetic counseling in cancer patients: A systematic review', Asia-Pacific Journal of Clinical Oncology, vol. 17, pp. 163 - 177, http://dx.doi.org/10.1111/ajco.13334

Lin HM; Huynh K; Kohli M; Tan W; Azad AA; Yeung N; Mahon KL; Mak B; Sutherland PD; Shepherd A; Mellett N; Docanto M; Giles C; Centenera MM; Butler LM; Meikle PJ; Horvath LG, 2021, 'Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, http://dx.doi.org/10.1038/s41391-021-00338-z

Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LJK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA, 2021, 'Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer', European Urology Focus, vol. 7, pp. 63 - 70, http://dx.doi.org/10.1016/j.euf.2019.04.020

Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath LG, 2021, 'Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer', JCO oncology practice, vol. 17, pp. e204 - e216, http://dx.doi.org/10.1200/OP.20.00399

Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham L-JK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA, 2021, 'Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.', JCO Precis Oncol, vol. 5, pp. 622 - 637, http://dx.doi.org/10.1200/PO.20.00424

Nindra U; Shahnam A; Mahon KL, 2021, 'Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13552

Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA, 2020, 'Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer', EBioMedicine, vol. 54, http://dx.doi.org/10.1016/j.ebiom.2020.102728

Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LJK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA, 2020, 'Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer', European Urology, vol. 78, pp. 173 - 180, http://dx.doi.org/10.1016/j.eururo.2020.03.044

Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG, 2020, 'Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)', BMJ Open, vol. 10, http://dx.doi.org/10.1136/bmjopen-2019-033667

Miladinovic D; Cusick T; Mahon KL; Haynes AM; Cortie CH; Meyer BJ; Stricker PD; Wittert GA; Butler LM; Horvath LG; Hoy AJ, 2020, 'Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localized prostate cancer', Cancers, vol. 12, http://dx.doi.org/10.3390/cancers12061385

Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath L, 2020, 'Evaluation of a mainstream model of genetic testing for men with prostate cancer.', Journal of Clinical Oncology, vol. 38, pp. 1521 - 1521, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1521

Quinn DI; Stricker PD; Kench JG; Grogan J; Haynes AM; Henshall SM; Grygiel JJ; Delprado W; Turner JJ; Horvath LG; Mahon KL, 2019, 'p53 nuclear accumulation as an early indicator of lethal prostate cancer', British Journal of Cancer, vol. 121, pp. 578 - 583, http://dx.doi.org/10.1038/s41416-019-0549-8

Zhang AY; Chiam K; Haupt Y; Fox S; Birch S; Tilley W; Butler LM; Knudsen K; Comstock C; Rasiah K; Grogan J; Mahon KL; Bianco-Miotto T; Ricciardelli C; Böhm M; Henshall S; Delprado W; Stricker P; Horvath LG; Kench JG, 2019, 'An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy', International Journal of Cancer, vol. 144, pp. 1151 - 1159, http://dx.doi.org/10.1002/ijc.31906

Brown KGM; Solomon MJ; Mahon K; O'Shannassy S, 2019, 'Management of colorectal cancer', The BMJ, vol. 366, http://dx.doi.org/10.1136/bmj.l4561

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, vol. 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG, 2019, 'Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial', European Urology, vol. 76, pp. 306 - 312, http://dx.doi.org/10.1016/j.eururo.2018.11.001

Mahon KL; Lin HM; Lee-Ng M; Cain D; Jacobs C; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano C; de BJS; Chi KN; Breit SN; Brown DA; Horvath LG, 2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p032

To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LJK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA, 2018, 'Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer', European Urology, vol. 73, pp. 818 - 821, http://dx.doi.org/10.1016/j.eururo.2018.01.007

Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG, 2017, 'Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer', British Journal of Cancer, vol. 116, pp. 1002 - 1011, http://dx.doi.org/10.1038/bjc.2017.50

Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; Prime C; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG, 2017, 'A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer', International Journal of Cancer, vol. 141, pp. 2112 - 2120, http://dx.doi.org/10.1002/ijc.30903

Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG, 2017, 'Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up', BJU International, vol. 120, pp. 651 - 658, http://dx.doi.org/10.1111/bju.13857

Zhang AY; Grogan JS; Mahon KL; Rasiah K; Sved P; Eisinger DR; Boulas J; Vasilaris A; Henshall SM; Stricker PD; Kench JG; Horvath LG, 2017, 'A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer', Annals of Oncology, vol. 28, pp. 1903 - 1909, http://dx.doi.org/10.1093/annonc/mdx247

Khoo TK; Yu B; Smith JA; Clarke AJ; Luk PP; Selinger CI; Mahon KL; Kraitsek S; Palme C; Boyer MJ; Dinger ME; Cowley MJ; O'Toole SA; Clark JR; Gupta R, 2017, 'Somatic mutations in salivary duct carcinoma and potential therapeutic targets', Oncotarget, vol. 8, pp. 75893 - 75903, http://dx.doi.org/10.18632/oncotarget.18173

Khoo T; Yu B; Smith J; Clarke A; Luk P; Selinger C; Mahon K; Kraitsek S; Palme C; Boyer M; Dinger M; Cowley M; O’Toole S; Clark J; Gupta R, 2017, 'Somatic mutations in salivary duct carcinoma and potential therapeutic targets', Pathology, vol. 49, pp. S105 - S105, http://dx.doi.org/10.1016/j.pathol.2016.12.301

Mahon KL; Qu W; Lin H-M; Spielman C; Cain D; Jacobs C; Chi KN; De Bono JS; Higano CS; Clark SJ; Horvath L, 2017, 'Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, vol. 35, pp. 5014 - 5014, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5014

Warton K; Mahon KL; Samimi G, 2016, 'Methylated circulating tumor DNA in blood: Power in cancer prognosis and response', Endocrine-Related Cancer, vol. 23, pp. R157 - R171, http://dx.doi.org/10.1530/ERC-15-0369

Bruce HM; Stricker PD; Gupta R; Savdie RR; Haynes AM; Mahon KL; Lin HM; Kench JG; Horvath LG, 2016, 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer', Prostate, vol. 76, pp. 1491 - 1500, http://dx.doi.org/10.1002/pros.23233

Mahon KL; Lin H-M; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler MR; Briscoe KP; Marx GM; Breit SN; Brown DA; Horvath L, 2016, 'Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, vol. 34, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.5039

Mahon KL; Lin HM; Castillo L; Lee BY; Lee-Ng M; Chatfield MD; Chiam K; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Daly RJ; Henshall SM; Horvath LG, 2015, 'Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer', British Journal of Cancer, vol. 112, pp. 1340 - 1348, http://dx.doi.org/10.1038/bjc.2015.74

Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ, 2014, 'Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer', British Journal of Cancer, vol. 111, pp. 1802 - 1809, http://dx.doi.org/10.1038/bjc.2014.463

Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG, 2014, 'Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer', British Journal of Cancer, vol. 110, pp. 2462 - 2471, http://dx.doi.org/10.1038/bjc.2014.181

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, vol. 31, pp. e22175 - e22175, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22175

Randall SA; Mckay MJ; Pascovici D; Mahon K; Horvath L; Clarke SJ; Molloy MP, 2012, 'Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry', Proteomics - Clinical Applications, vol. 6, pp. 626 - 634, http://dx.doi.org/10.1002/prca.201200039

Mahon K; Henshall SM; Horvath LG; Sutherland RL, 2011, 'Pathways of chemotherapy resistance in castration-resistant prostate cancer', Endocrine - Related Cancer, vol. 18, pp. 103 - 123, http://dx.doi.org/10.1530/ERC-10-0343

Mahon KL; Chatfield MD; Lee-Ng M; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Wykes R; Henshall SM; Sutherland RL; Horvath L, 2011, 'Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC).', JOURNAL OF CLINICAL ONCOLOGY, vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4598

Horvath L; Mahon KL; Qu W; Devaney J; Chatfield MD; Paul C; Wykes R; Boyer MJ; Stockler MR; Marx GM; Sutherland RL; Clark SJ, 2011, 'A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC).', JOURNAL OF CLINICAL ONCOLOGY, vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4603

Kao S; Mahon K; Lin B; Rutland J; Pawsey C; Mccaughan B; Beale P, 2009, 'Pleural well-differentiated papillary mesothelioma : A case report', Journal of Thoracic Oncology, vol. 4, pp. 920 - 922, http://dx.doi.org/10.1097/JTO.0b013e3181a97dc3

Kwan EM; Dai C; Fettke H; Hauser C; Bukczynska P; Ng N; Foroughi S; Graham L-JK; Mahon KL; Tan W; Wang A; Zhao Z; Zheng T; Zhou K; Yu J-J; Du P; Horvath L; Jia S; Kohli M; Azad A, 2021, 'Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.159

Kwan EM; Fettke H; Bukczynska P; Ng N; Hauser C; Graham L-JK; Mahon KL; Dai C; Xie F; Wang X; Zhao Z; Zhou K; Du P; Yu J; Jia S; Tan W; Horvath L; Kohli M; Azad A, 2020, 'Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 176 - 176, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.176

Horvath LG; Lin H-M; Mak B; Mahon K; Yeung N; Docanto M; Sutherland P; Shepherd A; Tan W; Azad A; Kohli M; Meikle P; Butler L, 2020, 'Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4761

Mahon KL; Lin H-M; Lee-Ng M; Stockler MR; Gurney H; Mallesara G; Briscoe KP; Marx GM; Higano CS; De Bono JS; Chi KN; Brown D; Breit SN; Horvath L, 2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, San Francisco, CA, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.230

Kwan EM; To SQ; Fettke HC; Docanto MM; Bukczynska P; Mant AM; Pook DW; Ng N; Graham L-JK; Segelov E; Mahon K; Davis ID; Parente P; Pezaro CJ; Horvath L; Azad A, 2019, 'Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, San Francisco, CA, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.188

Mak B; Mahon KL; Stockler MR; Joshua AM; Zhang AY; Parnis F; Meikle P; Horvath L, 2019, 'Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, San Francisco, CA, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS331

Mahon KL; Stricker P; Kench J; Grogan J; Delprado W; Turner J; Horvath L; Quinn DI, 2018, 'P53 as a predictor of clinical outcome in localized prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, San Francisco, CA, Vol. 36, presented at Genitourinary Cancers Symposium, San Francisco, CA, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.57

Kwan EM; To SQ; Fettke HC; Mant AM; Docanto MM; Bukczynska P; Ng N; Graham L-JK; Parente P; Pezaro CJ; Mahon KL; Horvath L; Todenhofer T; Azad A, 2018, 'Correlating whole blood AR-V7 and AR-V9 with therapy response to AR-targeted therapies in metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e17070

To SQ; Kwan E; Fettke H; Mant A; Docanto M; Martelotto L; Bukczynska P; Ng N; Graham L-J; Parente P; Pezaro C; Mahon K; Horvath L; Todenhoefer T; Azad A, 2018, 'AR-V7 and AR-V9 expression is not predictive of response to AR-axis targeting agents in metastatic castration-resistant prostate cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Chicago, IL, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Chicago, IL, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-2593

Horvath L; Lin H-M; Mahon KL; Weir J; Mundra P; Spielman C; Briscoe KP; Gurney H; Mallesara G; Marx GM; Stockler MR; Parton R; Hoy A; Daly RJ; Meikle P, 2017, 'The plasma lipidome in castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Chicago, IL, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5055

Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes R; Chatfield MD; Boyer MJ; Stockler MR; Marx GM; Gurney H; Gowda GMH; Molloy P; Horvath L; Clark SJ, 2014, 'Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, San Francisco, CA, presented at Genitourinary Cancers Symposium, San Francisco, CA, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.11

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockier MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 31 May 2013 - 04 June 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Breit S; Brown D; Molloy M; Marx G; Boyer M; Stockler M; Henshall S; Sutherland R; Horvath L, 2011, 'Cytokines' profiles to predict chemotherapy outcome in castration resistant prostate cancer (CRPC)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, Brussels, BELGIUM, pp. S22 - S22, presented at 5th European-Organisation-for-Research-and-Treatment-of-Cancer (EORTC)/National-Cancer-Institute (NCI)/American-Society-of-Clinical-Oncology (ASCO) Annual Meeting on Molecular Markers in Cancer, Brussels, BELGIUM, 27 October 2011 - 29 October 2011, http://dx.doi.org/10.1016/S0959-8049(11)72671-5